Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment

Area of Science:

• Cardiovascular biology and molecular medicine.
• Focus on heart failure pathogenesis and therapeutic targets.

Background:

• Heart failure (HF) is a major cause of mortality and hospitalization, despite advances in treatment.
• Existing models inadequately explain HF, hindering effective therapy development.
• Cardiomyocyte hypertrophy, an increase in heart cell mass, is a key feature in most HF forms.

Purpose of the Study:

• To review and outline recent insights into gene-silencing regulatory mechanisms driving cardiomyocyte hypertrophy.
• To highlight transcriptional control by histone deacetylases (HDACs) and post-transcriptional control by microRNAs as therapeutic targets.

Main Methods:

• Review of current literature on gene-silencing mechanisms in cardiomyocyte hypertrophy.
• Analysis of transcriptional regulation by HDACs.
• Examination of post-transcriptional regulation by microRNAs.

Main Results:

• Identified HDACs as key regulators of gene expression at the transcriptional level in cardiac hypertrophy.
• Highlighted microRNAs as critical players in post-transcriptional gene silencing relevant to cardiac hypertrophy.
• These mechanisms offer potential avenues for therapeutic intervention in heart failure.

Conclusions:

• Understanding HDACs and microRNAs provides critical insights into the molecular basis of cardiomyocyte hypertrophy.
• Targeting these gene-silencing pathways represents a promising strategy for developing novel heart failure therapies.
• Further research into these mechanisms could significantly improve outcomes for patients with heart failure.